Cell line · CVCL_1349
KYSE-180
Cancer cell line, Homo sapiens. Esophageal squamous cell carcinoma. 32 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. KYSE-180. Cell lines, record CVCL_1349. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1349
On this page
Cell line
As Cellosaurus gives it.
- Name
- KYSE-180
- Accession
- CVCL_1349
- RRID
- RRID:CVCL_1349
- Synonyms
- KYSE 180, KYSE180, Kyse180, KY180
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 53Y
- Category
- Cancer cell line
- Diseases
- Esophageal squamous cell carcinoma (NCIt C4024); Squamous cell carcinoma of the esophagus (ORDO Orphanet_99977)
- Derived from
- Esophagus (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers32
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Elevated CHAF1A Suppresses Type I Interferon Production and Causes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The AGPS regulatory variant rs113671272 confers esophageal squamous cell carcinoma susceptibility through allele-specific MEIS3 binding and NF-κB activation in Chinese populations. | EBioMedicine | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Circulating GPNMB-Based Multimodal Model Integrates Tumor-Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Patient-derived organoid xenografts model esophageal cancer cachexia and enable assessment of anti-inflammatory drug repositioning. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Clinofibrate Disrupts the SNORA80B/YTHDC1-Driven M6A Modification to Suppress Cholesterol Metabolism and Cisplatin Resistance in ESCC. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhancer demethylation-regulated gene score identified molecular subtypes, inspiring immunotherapy or CDK4/6 inhibitor therapy in oesophageal squamous cell carcinoma. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
Multigene Profiling of Circulating Tumor Cells in Esophageal Squamous Cell Carcinoma Identifies Prognostic Cancer Driver Genes Associated with Epithelial-Mesenchymal-Transition Progression and Chemoresistance. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Fibroblasts in metastatic lymph nodes confer cisplatin resistance to ESCC tumor cells via PI16. | Oncogenesis | 2023 | Its Methods give the RRID and name the line | PubMed | |
| A protein complex of LCN2, LOXL2 and MMP9 facilitates tumour metastasis in oesophageal cancer. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting LncRNA LLNLR-299G3.1 with antisense oligonucleotide inhibits malignancy of esophageal squamous cell carcinoma cells in vitro and in vivo. | Oncol Res | 2023 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 32
See all 32 papersRelatives0
None in this release.
Cell banks3
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| DSMZ | ACC-379 | DSMZ | |
| JCRB | JCRB1083 | JCRB | |
| JCRB | NIHS0347 | Discontinued | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1349
GET https://conductscience.org/api/cell-lines/v1/CVCL_1349/papers?page=2